CD8A and neoplasm: Novel breast cancer derived exosomes HELA-Exos were successfully used in triple-negative breast cancer (TNBC) mouse xenograft model and patient-derived tumor organoids, causing activation of DCs in tumor site and subsequent tumor reactive CD8+T cell infiltration, causing favorable tumor inhibition [9].